INS and memory impairment: Similarly, in a randomised controlled trial (NCT02503501), Rosenbloom et al. administered 20 IU of insulin glulisine twice daily to 35 memory-impaired individuals (aged 50–90 years) for 32 weeks using an Impel NeuroPharma I109 Precision Olfactory Delivery (POD®) device [2].